Hikma Pharmaceuticals PLC | Mutual Funds
Mutual Funds that own Hikma Pharmaceuticals PLC
American Funds EuroPacific Growth Fund
15,323,773
6.35%
0
0.28%
06/30/2018
Vanguard Health Care Fund
7,939,027
3.29%
0
0.41%
06/30/2018
Longleaf Partners International Fund
4,505,647
1.87%
0
9.49%
03/31/2018
American Funds New World Fund
3,835,400
1.59%
1,428,017
0.3%
06/30/2018
American Funds Insurance Series - International Fund
3,044,380
1.26%
0
0.9%
06/30/2018
American Funds Small Cap World Fund
2,841,100
1.18%
0
0.19%
06/30/2018
Genesis Emerging Markets Investment Co. - Global Sub Fund
2,454,191
1.02%
-384,326
0.92%
12/31/2017
Government Pension Fund - Global (The)
2,115,458
0.88%
-1,734,854
0.01%
12/31/2017
Vanguard Total International Stock Index Fund
1,996,944
0.83%
37,031
0.01%
07/31/2018
Emerging Markets Fund of the Genesis Group Trust for Employee
1,612,816
0.67%
957,111
0.49%
12/31/2016
| Address |
1 New Burlington Place
London Greater London W1S 2HR
United Kingdom
|
|
Employees
|
- |
| Website |
http://hikma.com |
| Updated |
07/08/2019 |
| Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, Generics, and Others. The Branded segment offers selling of branded generics and in-licensed patented products. |
